News

BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery

BenevolentAI will be proudly sponsoring NeurIPS again this year. Here are the details of our activities during the week:

Expo day: 6th December

How we leverage machine learning and AI to develop life-changing medicines - a case study with COVID-19.

The model for drug discovery and development is failing patients. It is expensive and high risk, with long research and development cycles. In this talk, we will discuss the peculiarities of machine learning across drug discovery, from the processing of scientific literature, to knowledge completion, target identification to precision medicine, to chemistry optimisation, each leveraging domain expert knowledge and state-of-the-art research and we will conclude our talk with a real example which will showcase the application of our technology and scientific expertise to repurpose existing drugs, as a potential treatment for COVID-19. 

Expo Schedule →

Meetup: 8th December

Application of Machine Learning to Drug Discovery Meetup

Why is drug discovery so complex? How can ML help to solve these scientific challenges? What does an ML applied drug discovery model look like? What skills are useful to the industry? If you are asking yourself some of these questions, then this meetup is for you.

Save your spot →


Our Research at NeurIPS

Learning Meaningful Representations of Life workshop:

Our AI Science Intern, Constantin Schneider, will present his paper on ‘Auxiliary task evaluations to learn meaningful representations from electronic health records', co-authored by BenevolentAI's Senior Machine Learning Researcher, Hamish Tomlinson, at the Learning Meaningful Representations of Life workshop.

Authors: Hamish Tomlinson, Constantin Schneider

----

Machine Learning for Molecules Workshop

Our team will be presenting their paper on 'Molecular representation learning with language models and domain-relevant auxiliary tasks' at the Machine Learning for Molecules Workshop.

Authors: Fabian et al. (2020)



Network with our team: join us on Hopin

While you're at NeurIPS, connect with our team virtually via the Hopin platform. Connect with our team at networking sessions to ask any questions you may have, and/or join our careers with impact meetup to learn more about what we do and how we work. The full programme will be coming soon. As we have limited space, we advise you to book your spot now.

Save your spot → Neurips Expo → Talent Pool →
More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022